Skip to main content
. 2023 Feb 1;11(2):e005545. doi: 10.1136/jitc-2022-005545

Figure 3.

Figure 3

Recombinant CXCL13 (rCXCL13) potentiates anti-PD-1 efficacy. (A) Schematic of experimental setup. C57BL/6 male mice were inoculated with 500,000 HKP1, 300,000 MC38 or 500,000 LLC1 cells into the flank. Representative CD8 IHC and H&E of (B) HKP1, (D) MC38, and (F) LLC1 treatment-naive tumors. Tumor growth curves of C57BL/6 wildtype mice inoculated with (C) HKP1, (E) MC38, or (G) LLC1 tumors with indicated treatments. Tumor sizes are shown as mean±SEM. HKP1 - rCXCL13+anti-PD1 versus PBS+anti-PD-1: ****p<0.0001, PBS+anti-PD1 versus PBS+IgG: **p=0.0067. MC38 - rCXCL13+anti-PD1 versus PBS+anti-PD-1: ***p=0.0001. Statistical analysis (C, E, G: two-way analysis of variance with Tukey multiple comparisons test). Scale bar on the H&E and IHC represents 100 µm. CRC, colorectal cancer; ICI, immune checkpoint inhibitor; IHC, immunohistochemistry; NK cell, natural killer cell; NSCLC, non-small cell lung cancer; PBS, phosphate-buffered saline; PD-1, programmed cell death protein-1; rCXCL13, recombinant CXCL13; Tc, cytotoxic T cell; Treg, regulatory T cell.